Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value.
Adv Ther
; 41(6): 2196-2216, 2024 Jun.
Article
in En
| MEDLINE
| ID: mdl-38767824
ABSTRACT
Despite advances in our understanding of the molecular landscape of prostate cancer and the development of novel biomarker-driven therapies, the prognosis of patients with metastatic prostate cancer that is resistant to conventional hormonal therapy remains poor. Data suggest that a significant proportion of patients with metastatic castration-resistant prostate cancer (mCRPC) have mutations in homologous recombination repair (HRR) genes and may benefit from poly(ADP-ribose) polymerase (PARP) inhibitors. However, the adoption of HRR gene mutation testing in prostate cancer remains low, meaning there is a missed opportunity to identify patients who may benefit from targeted therapy with PARP inhibition, with or without novel hormonal agents. Here, we review the current knowledge regarding the clinical significance of HRR gene mutations in prostate cancer and discuss the efficacy of PARP inhibition in patients with mCRPC. This comprehensive overview aims to increase the clinical implementation of HRR gene mutation testing and inform future efforts in personalized treatment of prostate cancer.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Recombinational DNA Repair
/
Prostatic Neoplasms, Castration-Resistant
/
Poly(ADP-ribose) Polymerase Inhibitors
/
Mutation
Limits:
Humans
/
Male
Language:
En
Journal:
Adv Ther
/
Adv. ther
/
Advances in therapy
Journal subject:
TERAPEUTICA
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: